Compare TG Therapeutics Inc (TGTX) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Wix.Com Ltd — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.36B), while Wix.Com Ltd trades at $73.87 (market cap $3.11B). The key difference: TG Therapeutics Inc is far larger — about 2.7× Wix.Com Ltd's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| TGTX | WIX | |
|---|---|---|
Market Cap | $8.36B | $3.11B |
Sector | Health | Technology |
52-Week High | $59.06 | $184.24 |
52-Week Low | $26.94 | $40.43 |
Enterprise Value | $8.57B | $4.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
WIX trades at $72.72, down 4.58% amid technical bearish signals and multiple securities class action lawsuits. The company shows revenue growth to $1.99B in 2025 but faces profitability challenges with a negative net income margin of -8.19%. Recent earnings were mixed with Q1 2026 missing expectations while Q2 2026 beat estimates. Cash flow trends show operational strength but significant investing outflows.
Analyst consensus remains positive with 63% buy ratings and $73.36 price target, but legal risks and competitive pressures create headwinds. The stock presents a high-risk opportunity with potential upside if legal issues resolve and AI product execution improves, though current technical weakness suggests caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
